I don't think the FDA has figured this out yet. I think the expectation from Kennedy, Enzi, Clinton, & Hatch is some sort of bioequivalence study. The legislation they proposed leaves it to the FDA to figure it out. BIO and MBC want the legislation to prescribe full clinical trials.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC